• Free US shipping for orders above $200
  • Search
  • Cart
Cagrilintide
  • IN-VITRO RESEARCH ONLY — NOT FOR HUMAN USE

Cagrilintide

Price range: £150.00 through £260.00

Cagrilintide is a long‑acting amylin analogue that regulates appetite, slows gastric emptying, and improves glucose control. By activating both amylin and calcitonin receptors, it enhances satiety, supports weight management, and shows promise in obesity and metabolic disorder research with once‑weekly dosing convenience.
  • Ships Today if ordered
  • Free international delivery within 1-3 business days on orders over $600, with a tracking number provided.
  • Third party tested
Characteristics
How does Cagrilintide work?
Research
Side Effects
Summary
References
Resource

Characteristics

Name
Cagrilintide
Type
Essential coenzyme found in all living cells
Function
Facilitates redox reactions, transferring electrons in metabolic pathways
Role in Metabolism
Critical for energy production via glycolysis, Krebs cycle, and oxidative phosphorylation
Forms
Cagrilintide (oxidized form) and NADH (reduced form)
Mechanism of Action
Acts as an electron carrier, regulates sirtuins and PARPs, supports DNA repair and cell signaling
Sources
Synthesized from dietary precursors like niacin (vitamin B3), nicotinamide riboside, and tryptophan

How does Cagrilintide work?

Cagrilintide is a long-acting synthetic analogue of the natural hormone amylin, designed to regulate appetite and energy balance. It works by activating both amylin and calcitonin receptors, which send strong satiety signals to the brain and slow the emptying of food from the stomach. This dual receptor action helps reduce hunger, prolong feelings of fullness, and improve glucose control after meals. By influencing metabolic pathways, Cagrilintide also supports better insulin sensitivity and healthier body composition. Its extended half-life allows for convenient once-weekly dosing, making it a promising candidate in research for obesity and metabolic disorders, often studied alongside GLP‑1 receptor agonists for enhanced weight management outcomes.

Research

Cagrilintide is a novel long-acting amylin analogue currently under investigation for its potential role in obesity and metabolic disorder management. Research focuses on its dual receptor activity, as it binds both amylin and calcitonin receptors to amplify satiety signals and regulate energy balance. Studies highlight its ability to slow gastric emptying, reduce food intake, and improve postprandial glucose control, making it a promising candidate for weight reduction protocols. Preclinical and clinical trials also explore its synergistic effects when combined with GLP‑1 receptor agonists, such as semaglutide, to enhance metabolic outcomes. Beyond appetite regulation, emerging research suggests possible benefits in insulin sensitivity, body composition, and even renal physiology, positioning Cagrilintide as a versatile agent in the evolving field of peptide-based therapeutics.

Side Effects

Cagrilintide, while showing promise in obesity and metabolic disorder research, may present certain side effects that require careful monitoring. The most commonly reported issues include gastrointestinal disturbances such as nausea, vomiting, constipation, or diarrhea, which are linked to its action of slowing gastric emptying. Some participants in clinical studies have also experienced decreased appetite to the point of reduced food tolerance, mild headaches, or fatigue. Because Cagrilintide influences satiety and metabolic pathways, it can occasionally cause fluctuations in blood glucose levels, particularly when combined with other antidiabetic agents. Long-term use is still under investigation, but researchers emphasize the importance of monitoring for sustained gastrointestinal tolerance and metabolic stability. Overall, side effects are generally mild to moderate and tend to diminish over time, yet they highlight the need for controlled dosing and ongoing clinical evaluation.

Summary

Cagrilintide is a novel long-acting amylin analogue currently under investigation for its potential role in obesity and metabolic disorder management. Research focuses on its dual receptor activity, as it binds both amylin and calcitonin receptors to amplify satiety signals and regulate energy balance. Studies highlight its ability to slow gastric emptying, reduce food intake, and improve postprandial glucose control, making it a promising candidate for weight reduction protocols. Preclinical and clinical trials also explore its synergistic effects when combined with GLP‑1 receptor agonists, such as semaglutide, to enhance metabolic outcomes. Beyond appetite regulation, emerging research suggests possible benefits in insulin sensitivity, body composition, and even renal physiology, positioning Cagrilintide as a versatile agent in the evolving field of peptide-based therapeutics.

References

Cagrilintide’s scientific foundation is supported by a growing body of peer-reviewed research exploring its role as a dual amylin and calcitonin receptor agonist. Key studies have examined its effects on appetite regulation, gastric emptying, and weight reduction in both preclinical models and human trials. Publications in journals such as Diabetes, Obesity and Metabolism and Nature Medicine highlight its potential when combined with GLP‑1 receptor agonists, showing enhanced metabolic outcomes and sustained weight loss. Additional research has investigated its influence on insulin sensitivity, body composition, and renal physiology, positioning Cagrilintide as a promising candidate in the evolving field of peptide-based therapeutics. These references emphasize the product’s credibility and provide a strong scientific basis for ongoing exploration in obesity and metabolic disorder management

Resource

Cagrilintide is supported by a range of scientific and educational resources that highlight its potential in obesity and metabolic disorder research. Researchers can access peer-reviewed journals, clinical trial data, and technical papers that explore its dual receptor activity, appetite regulation, and metabolic effects. Databases such as PubMed and ResearchGate provide verified studies, while specialized endocrinology and pharmacology archives offer deeper insights into its mechanism of action and therapeutic promise. Educational materials and conference proceedings further expand understanding of its role in combination therapies with GLP‑1 receptor agonists. These resources strengthen the credibility of Cagrilintide, positioning it as a valuable subject for ongoing exploration in peptide-based therapeutics and modern metabolic research.
SIZE:

5 mg, 10 mg

Reviews

There are no reviews yet.

Be the first to review “Cagrilintide”

Your email address will not be published. Required fields are marked *

Full access
Free for life

Member-only Access

Join to access all Chemists Peptidesresearch products with complete descriptions.
Get Full Access + 20% Discount

Why become a member?

  • Full access to our research peptide catalog.
  • Expert guidance for lab experiments.
  • Free educational resources on peptides.
  • Exclusive discounts on orders.
  • Latest insights via blogs and podcasts.

Your Trusted Partner for High-Quality Research Peptides

Peptide Chemists is more than a supplier of research-grade peptides, providing high-quality compounds that help laboratories achieve precise and reproducible results.

Superior Quality Assurance

Peptide Chemists ensures every peptide meets strict quality and purity standards through rigorous formulation and premium material sourcing.

Independently Validated

All products are tested in-house and by third-party labs, guaranteeing verified purity, concentration, and reliability.

Rapid Delivery & Professional Support

Peptide Chemists provides secure, prompt shipping and expert technical support for accurate and reliable laboratory use.

Scroll to Top